Role of 21-Gene Assay in HR+/HER2- Early Breast Cancer
Recent American Society of Clinical Oncology practice guidelines recommended the use of multigene assays (MGAs) to assist with decision-making for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer. Among the most widely used MGA is Oncotype DX, a 21-gene test; however, many gray areas exist in the application of this test. Read more.

Cognitive Effects of Tamoxifen, Exemestane in Postmenopausal Women
Endocrine therapy used in the management of hormone receptor–positive breast cancer has been associated with adverse effects on cognition. These agents may downregulate estrogen production or may block its activity. The hippocampus and frontal lobes of the brain are especially sensitive to these effects. Learn more about the results of studies examining the effect of endocrine therapy on cognition.

Palbociclib and Its Effect on Adverse Drug Events
Palbociclib is an oral chemotherapeutic agent (OCA) indicated for the treatment of advanced breast cancer with either initial endocrine-based therapy or in patients with disease progression following endocrine therapy. While there are advantages to the use of OCAs compared with parenteral products, including convenience and timesaving, there are also concerns about potential nonadherence and its adverse effects on survival. Read more.